Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dr. June Xu China

医疗基金
Website:
Redhillcapital.cn
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Investment opportunities
Headquartner in China
Yes
丹麓资本
Senior Associate 

Dr. Weihong Xu United States

Stanford Genome Technology Center
Website:
med.stanford.edu/sgtc
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
technology development partnership
Headquartner in China
No
Your Research Tool and Service name
genomics
SGTC
Director 

wenlian xu China

New drug development
Website:
GHtherapeutics.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
GH Therapeutics
CEO 

Mr. Kenneth Xu China

Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn

Website:
www.genova.cn
Company Size (Fulltime employees)
201-500
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
To work with a reputable pharmaceutical, or medical institute, or government agency, on scientific and business development of Novaferon as an antiviral drug for COVID-19. Cooperating specifically on organizing and managing international clinical trials, laboratory and animal studies for COVID-19. Licensing rights for COVID-19 applications of Novaferon in defined territories, further equity cooperation might be accordingly considered
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Genova Inc
Vice President & Corporate Secretary 
Functionality
Business Development

Mr. Paul Xu United States

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.
Website:
www.shenzhenoffice.org
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
providing consulting service for entities interested to find opportunities in Shenzhen
Headquartner in China
Yes
North American Rep. Office of Shenzhen
Business Development Specialist 
Functionality
Business Development

John Xu United States

We have a very unique T-cell engager Bi-specific antibody platform.

Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.

We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.

We are looking for China partners to codevelop the Bi-specific antibodies.

We are also raising the capital to set up the CHina subsidiary.

You can add my wechat: elite8800

Website:
www.Abpro.com
Partnering Objectives
Headquartner in China
No
Abpro
SVP 

Mrs. Shirley Xu China

Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.
Website:
http://www.yonghuacapital.com.cn/
Partnering Objectives
Headquartner in China
Yes
Yonghua Capital
Executive Director 
Functionality
Investment

Shawn Xu

Simcere Innovation
Managing Director and COO 

Siyuan Xu China

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.
Website:
www.visenpharma.com
Partnering Objectives
Headquartner in China
Yes
VISEN Pharmaceutical
Senior BD Manager 

Mr. Evan Xu China

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Website:
ir.genetronhealth.com
Company Size (Fulltime employees)
501-1000
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
N/A
Headquartner in China
Yes
Genetron Health
Chief Financial Officer 
Functionality
Management